PTU - Polskie Towarzystwo Urologiczne
list of articles:

Modern possibilities of magnetic resonanse (MR) imaging in the diagnostics of prostate cancer
Article published in Urologia Polska 2007/60/1.


Robert Chrzan 1, Andrzej Urbanik 1, Zygmunt Dobrowolski 2, Wacław Lipczyński 2
1 Katedra Radiologii Collegium Medicum, Uniwersytet Jagielloński
2 Klinika Urologii Collegium Medicum, Uniwersytet Jagielloński


prostate, prostate cancer, MR imaging, MR spectroscopy


Introduction and the aim of the study. MR using endorectal coil is a method of diagnostic imaging, allowing accurate presentation of prostate morphology, including differentiation of peripheral zone and central gland. Currently, it enables not only morphological imaging, but also assessment of metabolic disturbances and microcirculation abnormalities resulting from the presence of neoplasm. For a high cost and limited accessibility of MR, it is necessary to rationally determine its position in the algorithm of prostate cancer diagnostics and therapy. The aim of the study is to present modern possibilities of MR in the diagnostics of prostate cancer.
Material and method. On the basis of literature analysis, the current role of MR in the diagnostics and therapy of prostate cancer was determined. The currently available methods of prostate MR and their practical applications were presented.
Results. The MR technique in patients with suspected or confirmed prostate cancer at present includes not only morphological MR, but also MR spectroscopy, dynamic contrast enhanced MR and diffusion MR. Existing applications include, among other things: location of cancer focus in patients with both TRUS and sextant biopsy negative, tumor staging including extracapsular extension and the presence of metastatic pelvic lymph nodes and bone foci, optimization of radiotherapy, search for relapse, evaluation of hormone-deprivation therapy, biopsy under the MR guidance.
Conclusion. MR imaging using endorectal coil is a technique, useful both in the diagnostic process and in the therapy of prostate cancer, providing urologists with valuable information concerning not only morphological abnormalities, but also metabolic and microcirculation disturbances. Broader use of existing prostate MR possibilities is recommended, both in common urological practice and in scientific research.


  1. Wojciechowska U, Didkowska J, Tarkowski W, Zatoński W: Nowotwory złośliwe w Polsce w 2002 roku. Centrum Onkologii - Instytut im. M. Skłodowskiej-Curie, w: Krajowy Rejestr Nowotworów, Warszawa 2004, 28-66.
  2. Dobruch J, Borówka A, Antoniewicz A, Chłosta P: Badania przesiewowe mające na celu wczesne wykrycie raka stercza: uwarunkowania wynikające z epidemiologii i historii naturalnej. Metody diagnostyczne. Urol Pol 2004, 57, 12-22.
  3. Kuligowska E, Cieszanowski A: Strefowa koncepcja budowy stercza - zastosowanie kliniczne, w: Ultrasonografia gruczołu krokowego, Gdańsk, Wydawnictwo Medyczne MAKmed, 1997, str. 33-36.
  4. Kuligowska E, Cieszanowski A: Ultrasonograficzne badanie przezodbytnicze, w: Ultrasonografia gruczołu krokowego, Gdańsk, Wydawnictwo Medyczne MAKmed, 1997, str. 37-43.
  5. Hricak H, White S, Vigneron D et al: Carcinoma of the prostate gland: MR imaging with pelvic phased-array coils versus integrated endorectal-pelvic phased-array coils. Radiology 1994, 193, 703-709.
  6. Tacikowska M: Ocena skuteczności badania MR w przedoperacyjnym określeniu stopnia zaawansowania raka gruczołu krokowego, w korelacji z transrektalnym badaniem ultrasonograficznym. Nowotwory 2000, 50, 357-361.
  7. Beyersdorff D, Taupitz M, Winkelmann B et al: Patients with a History of Elevated Prostate-Specific Antigen Levels and Negative Transrectal US-guided Quadrant or Sextant Biopsy Results: Value of MR Imaging. Radiology 2002, 224, 701-706.
  8. Jager GJ, Ruijter ET, van de Kaa CA et al: Local staging of prostate cancer with endorectal MR imaging: correlation with histopathology. AJR 1996, 166, 845-852.
  9. Presti JC Jr, Hricak H, Narayan PA et al: Local staging of prostatic carcinoma: comparison of transrectal sonography and endorectal MR imaging. AJR 1996, 166, 103-108.
  10. Mirowitz SA, Brown JJ, Heiken JP: Evaluation of the prostate and prostatic carcinoma with gadolinium-enhanced endorectal coil MR imaging. Radiology 1993, 186, 153-157.
  11. Qayyum A, Coakley FV, Lu Y et al: Organ-confined prostate cancer: effect of prior transrectal biopsy on endorectal MRI and MR spectroscopic imaging. AJR 2004, 183, 1079-1083.
  12. van der Graaf M, Schipper RG, Oosterhof GO et al: Proton MR spectroscopy of prostatic tissue focused on the detection of spermine, a possible biomarker of malignant behavior in prostate cancer. MAGMA 2000, 10, 153-159.
  13. Kurhanewicz J, Vigneron DB, Nelson SJ et al: Citrate as an in vivo marker to discriminate prostate cancer from benign prostatic hyperplasia and normal prostate peripheral zone: detection via localized proton spectroscopy. Urology 1995, 45, 459-466.
  14. Kurhanewicz J, Vigneron DB, Hricak H et al: Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution. Radiology 1996, 198, 795-805.
  15. Kurhanewicz J, Vigneron DB, Nelson SJ: Three-dimensional magnetic resonance spectroscopic imaging of brain and prostate cancer. Neoplasia (New York) 2000, 2, 166-189.
  16. Chrzan R, Urbanik A, Dobrowolski Z, Lipczyński W: Morphological MRI and 3D proton spectroscopy using endorectal coil in the diagnostics of prostate cancer - preliminary experience. Pol J Radiol 2006, 71, 42-47.
  17. Scheidler J, Hricak H, Vigneron DB et al: Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging - clinicopathologic study. Radiology 1999, 213, 473-480.
  18. Hasumi M, Suzuki K, Taketomi A et al: The combination of multi-voxel MR spectroscopy with MR imaging improve the diagnostic accuracy for localization of prostate cancer. Anticancer Res 2003, 23, 4223-4227.
  19. Jung JA, Coakley FV, Vigneron DB et al: Prostate depiction at endorectal MR spectroscopic imaging: investigation of a standardized evaluation system. Radiology 2004, 233, 701-708.
  20. Yuen JS, Thng CH, Tan PH et al: Endorectal magnetic resonance imaging and spectroscopy for the detection of tumor foci in men with prior negative transrectal ultrasound prostate biopsy. J Urol 2004, 171, 1482-1486.
  21. Casciani E, Polettini E, Bertini L et al: Prostate cancer: evaluation with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiol Med 2004, 108, 530-541.
  22. Lowry M, Liney GP, Turnbull LW et al: Quantification of citrate concentration in the prostate by proton magnetic resonance spectroscopy: zonal and age-related differences. Magn Reson Med 1996, 36, 352-358.
  23. Zakian KL, Eberhardt S, Hricak H et al: Transition zone prostate cancer: metabolic characteristics at 1H MR spectroscopic imaging - initial results. Radiology 2003, 229, 241-247.
  24. Engelbrecht MR, Huisman HJ, Laheij RJ et al: Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging. Radiology 2003, 229, 248-254.
  25. Buckley DL, Roberts C, Parker GJ et al: Prostate cancer: evaluation of vascular characteristics with dynamic contrast-enhanced T1-weighted MR imaging - initial experience. Radiology 2004, 233, 709-715.
  26. Kim JK, Hong SS, Choi YJ et al: Wash-in rate on the basis of dynamic contrast-enhanced MRI: usefulness for prostate cancer detection and localization. J Magn Reson Imaging 2005, 22, 639-646.
  27. van Dorsten FA, van der Graaf M, Engelbrecht MR et al: Combined quantitative dynamic contrast-enhanced MR imaging and (1) H MR spectroscopic imaging of human prostate cancer. J Magn Reson Imaging 2004, 20, 279-287.
  28. Chan I, Wells W 3rd, Mulkern RV et al: Detection of prostate cancer by integration of line-scan diffusion, T2-mapping and T2-weighted magnetic resonance imaging, a multichannel statistical classifier. Med Phys 2003, 30, 2390-2398.
  29. Sato C, Naganawa S, Nakamura T et al: Differentiation of noncancerous tissue and cancer lesions by apparent diffusion coefficient values in transition and peripheral zones of the prostate. J Magn Reson Imaging 2005, 21, 258-262.
  30. Mueller-Lisse UG, Scherr M: 1H magnetic resonance spectroscopy of the prostate. Radiologe 2003, 43, 481-488.
  31. Wefer AE, Hricak H, Vigneron DB et al: Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. J Urol 2000,164, 400-404.
  32. Coakley FV, Qayyum A, Kurhanewicz J: Magnetic resonance imaging and spectroscopic imaging of prostate cancer. J Urol 2003, 170, S69-75.
  33. Claus FG, Hricak H, Hattery RR: Pretreatment evaluation of prostate cancer: role of MR imaging and 1H MR spectroscopy. Radiographics 2004, 24 Suppl 1, S167-180.
  34. Prando A, Kurhanewicz J, Borges AP et al: Prostatic biopsy directed with endorectal MR spectroscopic imaging findings in patients with elevated prostate specific antigen levels and prior negative biopsy findings: early experience. Radiology 2005, 236, 903-910.
  35. Amsellem-Ouazana D, Younes P, Conquy S et al: Negative prostatic biopsies in patients with a high risk of prostate cancer. Is the combination of endorectal MRI and magnetic resonance spectroscopy imaging (MRSI) a useful tool? A preliminary study. Eur Urol 2005, 47, 582-586.
  36. Partin AW, Yoo J, Carter HB et al: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993, 150, 110-114.
  37. Schnall MD, Connick T, Hayes CE et al: MR imaging of the pelvis with an endorectal-external multicoil array. J Magn Reson Imaging 1992, 2, 229-232.
  38. Yu KK, Scheidler J, Hricak H et al: Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiology 1999, 213, 481-488.
  39. Harisinghani MG, Barentsz J, Hahn PF et al: Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003, 348, 2491-2499.
  40. Borówka A, Dobruch J, Antoniewicz A: Przerzuty raka stercza do kości - objawy, rozpoznanie, patogeneza. Urol Pol 2006, 59, 17-22.
  41. Zaider M, Zelefsky MJ, Lee EK et al: Treatment planning for prostate implants using magnetic-resonance spectroscopy imaging. Int J Radiat Oncol Biol Phys 2000, 47, 1085-1096.
  42. Zelefsky MJ, Cohen G, Zakian KL et al: Intraoperative conformal optimization for transperineal prostate implantation using magnetic resonance spectroscopic imaging. Cancer J 2000, 6, 249-255.
  43. Menard C, Smith IC, Somorjai RL et al: Magnetic resonance spectroscopy of the malignant prostate gland after radiotherapy: a histopathologic study of diagnostic validity. Int J Radiat Oncol Biol Phys 2001, 50, 317-323.
  44. Coakley FV, Teh HS, Qayyum A et al: Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience. Radiology 2004, 233, 441-448.
  45. Pucar D, Shukla-Dave A, Hricak et al: Prostate cancer: correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy-initial experience. Radiology 2005, 236, 545-553.
  46. Mueller-Lisse UG, Swanson MG, Vigneron DB et al: Time-dependent effects of hormone-deprivation therapy on prostate metabolism as detected by combined magnetic resonance imaging and 3D magnetic resonance spectroscopic imaging. Magn Reson Med 2001, 46, 49-57.
  47. Zangos S, Eichler K, Engelmann K et al: MR-guided transgluteal biopsies with an open low-field system in patients with clinically suspected prostate cancer: technique and preliminary results. Eur Radiol 2005, 15, 174-182.
  48. Beyersdorff D, Winkel A, Hamm B: MR imaging-guided prostate biopsy with a closed MR unit at 1.5 T: initial results. Radiology 2005, 234, 576-581.
  49. Atalar E, Menard C: MR-guided interventions for prostate cancer. Magn Reson Imaging Clin N Am 2005, 13, 491-504.
  50. DiMaio SP, Pieper S, Chinzei K et al: Robot-assisted needle placement in open-MRI: system architecture, integration and validation. Stud Health Technol Inform 2006, 119, 126-131.


Robert Chrzan
Katedra Radiologii Collegium Medicum
ul. Kopernika 19
31-501 Kraków
tel. (012) 424 77 61